GlaxoSmithKline

Hosts discuss PARASOL Initiative's efforts to establish surrogate endpoints for FSGS trials, focusing on proteinuria as a robust predictor of kidney failure, potentially enabling smaller, faster trials.

Momelotinib improved anemia, increased transfusion independence rates, and alleviated symptoms and splenomegaly in myelofibrosis patients, especially those previously exposed to JAK inhibitors. The treatment showed sustained improvements in hemoglobin levels and reduced transfusion dependency, with a median reduction in spleen size of 5 cm. The study highlights momelotinib's effectiveness and safety profile in real-world settings.

COVID-19 treatment companies focus on vaccines, antivirals, monoclonal antibodies, and supportive care. Vaccines like Pfizer-BioNTech and Moderna reduce severe cases, while antivirals like Remdesivir and Paxlovid limit viral replication. Monoclonal antibodies like Bamlanivimab offer early intervention. Supportive care remains crucial. Market growth is driven by COVID-19 spread, new variants, and increased demand for effective therapies. Government investments and rapid vaccine advancements accelerate treatment availability. The global pulmonary drug delivery systems market is projected to reach USD 97.8 billion by 2033.

The PARASOL Initiative aims to revolutionize FSGS drug development by validating proteinuria as a therapeutic endpoint. Experts discuss how proteinuria reduction can accelerate approvals, emphasizing the need for addressing podocyte dysfunction. The initiative also focuses on specimen banking for biomarker discovery and collaborative research models for rare kidney diseases.

KEMRI researchers urge Kenya's Pharmacy and Poisons Board to approve Cabotegravir and Lenacapavir, injectable drugs with high efficacy in preventing HIV. Cabotegravir, requiring injections every eight weeks, and Lenacapavir, every six months, have shown significant prevention rates, approved by the FDA and EMA. Despite Cabotegravir's registration in Kenya, Lenacapavir's application is pending, and both drugs are costly, posing accessibility challenges. KEMRI appeals for faster approvals to reduce HIV infections in Kenya.

GSK entered strategic deals with Relation and Muna Therapeutics in Dec 2024 to advance drug development for fibrotic diseases, osteoarthritis, and Alzheimer’s disease. GSK paid $45M and €33.5M upfront respectively, with potential milestone payments up to $200M and €140M per target. Both collaborations aim to identify and validate novel therapeutic targets using advanced platforms.

Relation announced two strategic collaborations with GSK to identify novel therapeutic targets for fibrotic diseases and osteoarthritis, receiving $45M upfront. The collaborations leverage Relation's Lab-in-the-Loop platform, combining human genetics, single-cell multi-omics, functional assays, and machine learning. GSK gains worldwide rights to resulting targets, with potential milestone payments up to $200M per target.

FDA detected severe side effects in Moderna's mRNA-1345 and mRNA-1365 RSV vaccine candidates for infants, with blunted responses to prophylactic antibody Beyfortus. VRBPAC will discuss safety findings, implications for pediatric development, and potential interactions between RSV prophylactic antibodies and vaccines. mRNA-1345 is approved for adults aged 60+ and continues in high-risk adults and pediatric populations. mRNA-1365, a combination vaccine for RSV and human metapneumovirus, is in Phase I. Moderna paused mRNA-1365 study due to severe RSV LRTI cases.

Herpes simplex 1 and 2, which cause cold sores, remain incurable and can reactivate due to stress. Antiviral medications can manage outbreaks but not eliminate the virus. Researchers are exploring vaccines and gene therapy for prevention and treatment, with some promising early-stage trials.

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.